Small molecule · Inhibitor of uric acid transporter 1 (URAT1) (SLC22A12) and organic anion transporter 4 (OAT4) (SLC22A11) · developed by Ironwood Pharms
Lesinurad is a uric acid reabsorption inhibitor that reduces serum uric acid levels by inhibiting URAT1 and OAT4 transporters in the kidney, increasing uric acid excretion. It is used in combination with allopurinol for treatment of hyperuricemia associated with gout in patients inadequately controlled on allopurinol alone.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 18, 2018). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03226899 | Phase 4 | Gout | Terminated | IRWD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Kidney Disease (CKD)Gout
Updated Oct 3, 2026. Something wrong or missing? Report it on the IRWD page.
See IRWD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IRWD catalysts and pipeline →